<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:VBLT (Israel)

Vascular Biogenics Ltd $ 1.31 0.01 (0.77%)

Volume:
2,736
Avg Vol (1m):
24,043
Market Cap $:
47.00 Mil
Enterprise Value $:
5.12 Mil
P/E (TTM):
0.00
P/B:
1.03
Warning! GuruFocus has detected 2 Severe warning signs with VBLT. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)

VBLT News and Headlines - Vascular Biogenics

GuruFocus Articles Total 34
  • 1
  • 2

Conference Call and Webcast at 8:30am Eastern Time Today

TEL AVIV, Israel, Aug. 13, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate update.

“Our OVAL Phase 3 potential-registration trial of VB-111 in ovarian cancer continues as planned,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “The final results from the prior Phase 2 study (presented at ASCO in June) which show statistically significant prolongation of overall

0 Views    Marketwired    2019-08-13 12:01

TEL AVIV, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Tuesday, August 13 at 8:30am Eastern Time to report second quarter and six-months ended June 30, 2019 financial results and to provide a corporate update.

Tuesday, August 13th @ 8:30am Eastern Time
VBLT
0 Views    Marketwired    2019-08-05 16:04

TEL AVIV, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that its new gene therapy manufacturing facility in Modiin, Israel, has been approved by a European Union (EU) Qualified Person (QP) as being in compliance with EU Good Manufacturing Practices (GMP).

“EU-GMP standards are very high, and having our Modiin manufacturing facility approved on its first audit not only represents the excellence VBL aspires to,

0 Views    Marketwired    2019-07-22 16:05

TEL AVIV, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the recent VB-111 progress, including data presented earlier this week at the 2019 ASCO Annual Meeting. The presentation will be also available to the investor audience by webcast.

2019 BIO International Convention
0 Views    Marketwired    2019-06-04 12:01

  • VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03)

  • CA-125 response (GCIG) was reported in 58% of evaluable patients and was predictive of overall survival, in patients treated with a therapeutic dose of VB-111

  • Post treatment tumor infiltrating CD8 T-cells and apoptotic cancer cells indicated tumor transformation from immunologically ‘cold’ to ‘hot’, possibly contributing to the favorable clinical outcomes

  • Fever response to VB-111 occurred in 29% of patients and was associated with favorable overall survival

TEL AVIV, Israel, June 03,

0 Views    Marketwired    2019-06-03 16:02

TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, showed a survival benefit associated with objective responses to the compound and a distinct signature of VB-111 activity. The data were presented by Dr. Benjamin M. Ellingson, Ph.D., from the UCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Science.

The UCLA analysis

0 Views    Marketwired    2019-06-03 16:01

TEL AVIV, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, to be held May 31 - June 4, 2019 in Chicago, Illinois. An additional presentation at ASCO will focus on analysis of VB-111 MRI data from Phase 2 and Phase 3 studies in recurrent GBM and the potential of VB-111 in

0 Views    Marketwired    2019-05-23 16:00

Conference Call and Webcast at 8:30am Eastern Time Today

TEL AVIV, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT) today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update.

“As we continue to advance development of VB-111, we are getting a better understanding of its mechanism of action and how best to incorporate it into oncology treatment regimens,” said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. “We expect two additional VB-111

0 Views    Marketwired    2019-05-15 12:00

TEL AVIV, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Wednesday, May 15 at 8:30am Eastern Time to report first quarter ended March 31, 2019 financial results and to provide a corporate update.

Wednesday, May 15th @ 8:30am Eastern Time
From the US: VBLT
0 Views    Marketwired    2019-05-06 16:00

TEL AVIV, Israel, March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting, to be held March 29 - April 3, 2019 at Georgia World Congress Center in Atlanta, Georgia. VB-111 is a first-in-class, targeted anti-cancer gene-therapy biologic with broad potential to treat a wide range of solid tumors. In addition, the company will provide

0 Views    Marketwired    2019-03-25 16:01

Data Presented at Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer®

TEL AVIV, Israel, March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111 has potential to stimulate the immune system to induce a strong and durable response against ovarian tumors. Administration of VB-111 was associated with an infiltration of immune cells within the tumor, which was followed by tumor necrosis

0 Views    Marketwired    2019-03-19 12:00

TEL AVIV, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 28th at 8:30am Eastern Time to report fiscal year ended December 31, 2018 financial results and to provide a corporate update.

Thursday, March 28th @ 8:30am Eastern Time
From the
0 Views    Marketwired    2019-03-14 12:00

TEL AVIV, Israel, March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase 3 candidate VB-111, at the SGO 50th Annual Meeting on Women's Cancer, to be held March 16 - 19, 2019 at the Hawaii Convention Center in Honolulu, Hawaii.

VBLT
0 Views    Marketwired    2019-03-11 12:01

TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of various inflammatory indications, including NASH and RA. Previously, the Company has demonstrated efficacy of anti-MOSPD2 monoclonal antibodies in multiple sclerosis (MS) models, and novel findings now implicate MOSPD2 as a potential target for NASH and RA as well.  VBL's study entitled “MOSPD2:

0 Views    Marketwired    2019-02-26 17:05

TEL AVIV, Israel, Feb. 20, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of over 10 million New Israeli Shekels (approximately $2.9 million) by the Israel Innovation Authority (IIA) for 2019.  The funds will support the continued development of the Company’s lead product candidate, VB-111, a first-in-class targeted anti-cancer gene-therapy agent. The Company is currently evaluating VB-111 in a potential registration study (OVAL) for the treatment of platinum-resistant ovarian cancer, with further plans to

0 Views    Marketwired    2019-02-20 13:07

TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), today announces that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2 for inflammatory and oncology indications, at the Keystone Symposia on Myeloid Cells, to be held February 24—28, 2019 at the Eldorado Hotel & Spa in Santa Fe, New Mexico.

Oral Presentation Details:  
VBLT
0 Views    Marketwired    2019-02-19 17:08

TEL AVIV, Israel, Nov. 21, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate update, in a Fireside Chat format, at the Piper Jaffray 30th Annual Healthcare Conference, to be held at the Lotte New York Palace on November 27–29, 2017, in New York City.

0 Views    Marketwired    2018-11-21 13:01

Additional Analyses Provide Insight into Treatment Effect of VB-111

TEL AVIV, Israel, Nov. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), is reporting results today from its Phase 3 GLOBE study in patients with recurrent glioblastoma (rGBM) which was designed to evaluate VB-111 in combination with bevacizumab (Avastin®) (`treatment arm`), compared to bevacizumab (`control arm`).  In March 2018, VBL announced top-line data for the study, which did not demonstrate a benefit in overall survival (OS) or progression-free survival for the treatment arm relative to the

0 Views    Marketwired    2018-11-16 13:04

TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics ( VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Tuesday, November 20 at 8:30am Eastern Time to report third quarter ended September 30, 2018 financial results and to provide a corporate update.

Presentation Details:
Tuesday, November 20th @ 8:30am Eastern Time
VBLT
0 Views    Marketwired    2018-11-13 13:03

TEL AVIV, Israel, Oct. 23, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), today announced the issuance by the European Patent Office (EPO) of Patent No. 2908865, a composition of matter patent which covers VB-111, VBL's lead drug candidate. The patent provides intellectual property protection for VB-111 in Europe until October 2033, before any potential extension. The patent further strengthens the VB-111 intellectual property portfolio, which comprises multiple granted patents including composition of matter patents in the US, Japan, China and additional countries.

“VBL is focused

0 Views    Marketwired    2018-10-23 16:05

Headlines Total 67
  • 1

2019-08-13 $ 1.25 (4.17%)
2:25pm
7:25am
7:01am
2019-08-06 $ 1.15 (-1.71%)
9:30am
2019-08-05 $ 1.17 (-8.59%)
11:04am
2019-07-22 $ 1.32 (-1.49%)
11:05am
2019-06-06 $ 1.19 (-1.65%)
1:49pm
2019-06-04 $ 1.2 (-4.76%)
7:01am
2019-06-03 $ 1.26 (-8.03%)
11:02am
11:01am
2019-05-23 $ 1.3 (-2.26%)
11:00am
2019-05-15 $ 1.21 (-2.42%)
11:45am
7:15am
7:00am
2019-05-14 $ 1.24 (0.81%)
5:16pm
2019-05-08 $ 1.25 (-3.85%)
9:30am
2019-05-06 $ 1.32 (3.13%)
11:00am
2019-03-28 $ 1.56 (-3.7%)
4:51pm
10:21am
2019-03-25 $ 1.54 (-4.35%)
11:01am
2019-03-21 $ 1.63 (-4.12%)
9:30am
2019-03-19 $ 1.75 (2.34%)
7:00am
2019-03-14 $ 1.67 (-0.6%)
9:30am
7:00am
2019-03-11 $ 1.64 (%)
7:01am
2019-02-26 $ 1.6 (6.67%)
11:05am
2019-02-20 $ 1.42 (0.71%)
7:07am
2019-02-19 $ 1.41 (2.92%)
11:08am
2019-01-23 $ 1.18 (%)
3:56pm
2018-11-21 $ 1.19 (3.48%)
7:01am
2018-11-20 $ 1.15 (2.68%)
2:09pm
7:15am
2018-11-16 $ 1.1 (-3.51%)
7:04am
2018-11-13 $ 1.22 (-3.94%)
7:03am
2018-10-23 $ 1.36 (0.74%)
11:05am
2018-10-16 $ 1.4 (0.72%)
7:54am
2018-10-11 $ 1.43 (-7.74%)
7:02am
2018-09-17 $ 1.6 (%)
11:10am
2018-08-30 $ 1.68 (1.82%)
7:01am
2018-08-16 $ 1.65 (-2.94%)
12:25pm
7:15am
2018-08-01 $ 1.93 (-1.03%)
11:08am
2018-07-10 $ 2.15 (0.94%)
11:05am
2018-06-27 $ 2.3 (-1.29%)
7:00pm
2018-06-26 $ 2.33 (-8.63%)
11:01am
2018-06-05 $ 2.15 (0.94%)
7:02pm
2018-05-07 $ 2.2 (%)
11:05am
2018-05-01 $ 2.23 (1.36%)
11:05am
2018-04-27 $ 2.2 (%)
7:44am
2018-04-16 $ 2.25 (-6.25%)
11:04am
2018-04-12 $ 2.33 (1.3%)
7:52am
2018-04-10 $ 2.25 (7.14%)
11:02am
2018-04-09 $ 2.1 (0.96%)
11:01am
2018-03-13 $ 2.43 (-2.8%)
11:53am
2018-03-12 $ 2.5 (-3.85%)
8:00am
2018-03-09 $ 2.6 (-1.89%)
4:20pm
11:51am
2018-01-02 $ 7.2 (1.41%)
7:30am
2017-12-18 $ 6.65 (-0.75%)
7:41am
2017-11-22 $ 7 (0.72%)
8:44am
2017-11-17 $ 6.85 (-23.89%)
11:55am
2017-11-09 $ 7.4 (0.68%)
11:21am
2017-10-30 $ 5.95 (-1.65%)
9:16am
2017-10-03 $ 6.1 (1.67%)
7:01am
2017-10-02 $ 6 (4.35%)
12:06pm
2017-05-06
7:04am
2017-05-02 $ 5.85 (%)
8:36am
Total 67
  • 1